美国 中文 English 2024-08更新 企业注册号: 874732 成立日期: 1985-06-24 企查查编码: QUS4DSNN52 办公地址: - 基本信息 企业注册号 874732 企业名称 IDEC, INC. 企业状态 ACTIVE 成立日期 1985-06-24 企业类型 - 注册地 PENNSYLVANIA(宾夕法尼亚州) ...
The article focuses on Weston, Massachusetts-based Biogen Idec Inc. which will work with San Diego, California-based Regulus Therapeutics Inc. to identify microRNAs biomarkers in patients with multiple sclerosis. It states that Biogen wil...
股票 美国(NYSE/NASDAQ) BIOGEN IDEC Inc (BIIB) 15分钟延迟 交易条款 交易时间 (UTC) 星期一: 11:00 - 00:00 星期二 - 星期五: 00:00 - 00:30, 11:00 - 00:00 星期六: 00:00 - 00:30 费率和条款 买入 卖出 统计数据 资本总额 $22,012 百万 行业 Biotechnology 上一交易日 $ ...
BIOGEN IDEC INC. ANNUAL REPORT ON FORM 10-K For the Year Ended December 31, 2009 TABLE OF CONTENTS Page PART I Item 1. Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....
Biogen Idec Patient Support As part of its ongoing commitment to the MS community, Biogen Idec provides a variety of support services for patients and caregivers through MS ActiveSource®. These world-class services are thoughtfully crafted around the informational, emotional, financial a...
CAMBRIDGE, Ma. & HAWTHORNE, N.Y.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) and Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize Fampridine-...
Biogen Idec, Inc. In January 2015 the company announced it will acquire for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pi... B Idec - 《Howard Birndorf》 被引量: 9发表: 2013年 ORA FOIA Electronic Reading Room - Biogen Idec. Inc. In...
Biogen Idec, Inc. 来自 chemeurope.com 喜欢 0 阅读量: 22 作者: B Idec 摘要: In January 2015 the company announced it will acquire for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pipeline, in-particular CNV1014802 – a Phase II small...
$生化基因(BIIB)$. Biogen Idec Inc. (NASDAQ: BIIB) today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. The revenue growth year-over-year was driven by strong TECFIDERA performance and from recording 100% of TY...
原料品名 MURINE MONOCLONAL ANTIBODY (2B8) TO CD20 美国DMF登记 暂无权限 供应商信息 企业名称 BIOGEN IDEC INC 备注 若未能联系上供应商,可在药智通发布求购信息(https://s.yaozh.com/Purchase/release),或联系药智通客服17318480790(微信同号) 扩展信息 ...